Return on Equity (ROE): 18.15%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 18.15% is 12% below its 5-year average of 20.56%, near the low end of its 5-year range (15.54%–28.34%).
As of Saturday, June 27, 2026. 7.05% above its 12-month average of 16.95%.
WST Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
WST Average Return on Equity (ROE) Chart
WST Current vs Average Return on Equity (ROE) Chart
WST Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
18.15%
RETURN ON EQUITY (ROE) AVG TTM
16.95%
RETURN ON EQUITY (ROE) AVG 3Y
19.08%
RETURN ON EQUITY (ROE) AVG 5Y
20.56%
RETURN ON EQUITY (ROE) AVG 10Y
17.04%
RETURN ON EQUITY (ROE) AVG 15Y
15.39%
RETURN ON EQUITY (ROE) AVG 20Y
14.62%
CURRENT VS TTM AVG
+7.05%
CURRENT VS 3Y AVG
-4.89%
CURRENT VS 5Y AVG
-11.71%
CURRENT VS 10Y AVG
+6.49%
CURRENT VS 15Y AVG
+17.96%
CURRENT VS 20Y AVG
+24.11%
WST Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.79B | 18.15% | 16.95% | 19.08% | 20.56% |
| Waters Corporation (WAT)vs › | $24.41B | 2.94% | 29.98% | 64.02% | 111.55% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.44B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| Moderna, Inc. (MRNA)vs › | $26.35B | -43.12% | -32.64% | -13.90% | 0.25% |
| Quest Diagnostics Incorporated (DGX)vs › | $23.08B | 13.90% | 13.34% | 14.07% | 18.07% |
| BioNTech SE (BNTX)vs › | $23.07B | -6.79% | -4.55% | 10.63% | 21.70% |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 21.82% | 18.68% | 17.25% | 16.03% |
| DexCom, Inc. (DXCM)vs › | $26.76B | 31.47% | 28.93% | 25.01% | 22.95% |
| Incyte Corporation (INCY)vs › | $22.73B | 25.79% | 12.92% | 11.29% | 9.83% |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 10.79% | 9.71% | 9.35% | 12.84% |
Return Analysis
ROE
18.1%
ROA
13.2%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for West Pharmaceutical Services, Inc. (WST)?
- The return on equity (ROE) for WST stock is 18.15%.
- Is West Pharmaceutical Services, Inc.'s return on equity (ROE) high or low?
- The return on equity (ROE) of 18.15% is 12% below its 5-year average of 20.56%, near the low end of its 5-year range (15.54%–28.34%).
- What is the TTM average return on equity (ROE) for West Pharmaceutical Services, Inc. (WST)?
- The TTM average return on equity (ROE) for WST stock is 16.95%.
- What is the 3Y average return on equity (ROE) for West Pharmaceutical Services, Inc. (WST)?
- The 3Y average return on equity (ROE) for WST stock is 19.08%.
- What is the 5Y average return on equity (ROE) for West Pharmaceutical Services, Inc. (WST)?
- The 5Y average return on equity (ROE) for WST stock is 20.56%.
- What is the 10Y average return on equity (ROE) for West Pharmaceutical Services, Inc. (WST)?
- The 10Y average return on equity (ROE) for WST stock is 17.04%.
- What is the 15Y average return on equity (ROE) for West Pharmaceutical Services, Inc. (WST)?
- The 15Y average return on equity (ROE) for WST stock is 15.39%.
- What is the 20Y average return on equity (ROE) for West Pharmaceutical Services, Inc. (WST)?
- The 20Y average return on equity (ROE) for WST stock is 14.62%.
WST Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 15.54% |
| 2024-12-31 | 18.37% |
| 2023-12-31 | 20.60% |
| 2022-12-31 | 21.82% |
| 2021-12-31 | 28.34% |
| 2020-12-31 | 18.67% |
| 2019-12-31 | 15.36% |
| 2018-12-31 | 14.82% |
| 2017-12-31 | 11.77% |
| 2016-12-31 | 12.85% |
| 2015-12-31 | 9.34% |
| 2014-12-31 | 13.28% |
| 2013-12-31 | 12.39% |
| 2012-12-31 | 11.07% |
| 2011-12-31 | 11.53% |
| 2010-12-31 | 10.44% |
| 2009-12-31 | 12.54% |
| 2008-12-31 | 17.66% |
| 2007-12-31 | 14.57% |
| 2006-12-31 | 16.19% |
| 2005-12-31 | 13.67% |
| 2004-12-31 | 6.44% |
| 2003-12-31 | 12.38% |
| 2002-12-31 | 9.13% |
| 2001-12-31 | -2.94% |
| 2000-12-31 | 0.78% |
| 1999-12-31 | 16.74% |
| 1998-12-31 | 2.91% |
| 1997-12-31 | 15.99% |
| 1996-12-31 | 6.51% |
Related Metrics
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green